Ann: Larry Glass to retire as a director and continue as CSO, page-8

with this innovation it is even more evident how fast the company is progressing with NNZ-2591; Dr. Glass has always been Neuren's absolute protagonist with his projects and objectives that we know well have been structured in the past. Dr. Glass has a past in a multinational biotech, but even more servant of the American army that I remember is the only subject mentioned in the latest official communication on the preclinical experimentation of the NNZ-2591.
Given this, I think it is obvious that everything that is maturing day by day was decided on the occasion of the agreement with Acadia dell'Agosto last; the appointment of the three managers, the activation of the period of discussions for the global trofinetide option and today the concentration of Glass in the experimentation process, are the clear intent of distributing the roles and the skills to better face the big and main Neuren's usual challenge for ambitions and content. Neuren will demand from the negotiation with Acadia the full commitment of the Trofinetide package, including FX and related rights in exchange for sufficient capital to advance 2591 at least to phase 2 of experimentation with the strategic / operational contribution of the American military, who enjoy undisputed preferred lanes both in terms of facilitation in enrollment that facilitations for regulation. the circle is closing, finding the point from which we started, namely the design and development of a secret and parallel 2591 through the results of 2566 today Trofinetide.
should also be noted that a certain type of announcements such as today, are official in the last hours of the year (see that related to Hancox December 27 last), while today's is well in advance, perhaps to leave room for news of a certain weight that frankly they are mature and more than ever opportune.
good luck to all.